Emixustat

Phase 2Small molecule

Emixustat is one of 93 small molecule programs targeting Proliferative Diabetic Retinopathy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Proliferative Diabetic RetinopathyActive, not recruiting

AtrophyActive, not recruiting

Age-Related Macular DegenerationActive, not recruiting

Proliferative Diabetic RetinopathyPhase 2

Active, not recruiting

AtrophyPhase 2

Active, not recruiting

Age-Related Macular DegenerationPhase 1

Active, not recruiting

Competition

Competitive Landscape

237 competitors in Age-Related Macular Degeneration

#DrugCompanyPhaseTrials

Lucentis

Roche

Phase 3

64 2

Eylea

Regeneron

Phase 3

44 3

Vabysmo

Roche

Phase 3

13 4

Beovu

Novartis

Phase 3

10 5

Macugen

Pfizer

Phase 3

6 6

Avastin

BBio-Thera Solutions

Phase 3

18 7

Retaane

AAlcon Research

Phase 3

5 8

Forzinity

SStealth BioTherapeutics Inc.

Phase 3

2 9

Kenalog

BBausch Health Americas, Inc.

Phase 3

2 10

Aquasol E

NNational Eye Institute (NEI)

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Atrophy1 trial

Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease

Completed·KKubota Vision Inc.·Phase 2·NCT03033108·23 enrolled

Age-Related Macular Degeneration1 trial

Pharmacokinetic and Pharmacodynamic Study of Emixustat in Subjects With Geographic Atrophy Associated With Dry Age-Related Macular Degeneration

Completed·KKubota Vision Inc.·Phase 1·NCT02130531·26 enrolled

Proliferative Diabetic Retinopathy1 trial

Study to Evaluate Effects of Emixustat Hydrochloride in Subjects With Proliferative Diabetic Retinopathy

Completed·KKubota Vision Inc.·Phase 2·NCT02753400·24 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of Emixustat in Stargardt Disease

Completed·KKubota Vision Inc.·Phase 3·NCT03772665·194 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Emixustat. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Emixustat compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Emixustat. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kubota Vision Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: KKubota Vision Inc.

Emixustat

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Atrophy1 trial

Age-Related Macular Degeneration1 trial

Proliferative Diabetic Retinopathy1 trial

Safety and Efficacy1 trial

References

Drug Info

Quick Facts

Related News